Literature DB >> 28471885

Extracorporeal Membrane Oxygenation for Acute Decompensated Heart Failure.

Laurence Dangers1, Nicholas Bréchot, Matthieu Schmidt, Guillaume Lebreton, Guillaume Hékimian, Ania Nieszkowska, Sébastien Besset, Jean-Louis Trouillet, Jean Chastre, Pascal Leprince, Alain Combes, Charles-Edouard Luyt.   

Abstract

OBJECTIVE: Long-term outcomes of patients treated with venoarterial-extracorporeal membrane oxygenation for acute decompensated heart failure (i.e., cardiogenic shock complicating chronic cardiomyopathy) have not yet been reported. This study was undertaken to describe their outcomes and determine mortality-associated factors.
DESIGN: Retrospective analysis of data prospectively collected.
SETTING: Twenty-six-bed tertiary hospital ICU. PATIENTS: One hundred five patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensated heart failure. INTERVENTION: None.
MEASUREMENTS AND MAIN RESULTS: From March 2007 to January 2015, 105 patients were implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensated heart failure in our ICU (67% of them had an intraaortic balloon pump to unload the left ventricle). Their 1-year survival rate was 42%; most of the survivors were transplanted either directly or after switching to central bilateral centrifugal pump, ventricular-assist device, or total artificial heart. Most deaths occurred early after multiple organ failure. Multivariable analyses retained (odds ratio [95% CI]) pre-extracorporeal membrane oxygenation Sequential Organ Failure Assessment score of more than 11 (3.3 [1.3-8.3]), idiopathic cardiomyopathy (0.4 [0.2-1]), cardiac disease duration greater than 2 years pre-extracorporeal membrane oxygenation (2.8 [1.2-6.9]), and pre-extracorporeal membrane oxygenation blood lactate greater than 4 mmol/L (2.6 [1.03-6.4]) as independent predictors of 1-year mortality. Only 17% of patients with pre-extracorporeal membrane oxygenation Sequential Organ Failure Assessment scores of 14 or more survived, whereas 52% of those with scores less than 7 and 60% of those with scores 7 or more and less than 11 were alive 1 year later.
CONCLUSIONS: Among this selected cohort of 105 patients implanted with venoarterial-extracorporeal membrane oxygenation for acute decompensated heart failure, 1-year survival was 42%, but better for patients with pre-extracorporeal membrane oxygenation Sequential Organ Failure Assessment scores of less than 11. Venoarterial-extracorporeal membrane oxygenation should be considered for patients with acute decompensated heart failure, but timing of implantation is crucial.

Entities:  

Mesh:

Year:  2017        PMID: 28471885     DOI: 10.1097/CCM.0000000000002485

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  14 in total

Review 1.  ECMO and Short-term Support for Cardiogenic Shock in Heart Failure.

Authors:  Mathew Jose Chakaramakkil; Cumaraswamy Sivathasan
Journal:  Curr Cardiol Rep       Date:  2018-08-16       Impact factor: 2.931

2.  Percutaneous versus surgical femoro-femoral veno-arterial ECMO: a propensity score matched study.

Authors:  Pichoy Danial; David Hajage; Lee S Nguyen; Ciro Mastroianni; Pierre Demondion; Matthieu Schmidt; Adrien Bouglé; Julien Amour; Pascal Leprince; Alain Combes; Guillaume Lebreton
Journal:  Intensive Care Med       Date:  2018-11-14       Impact factor: 17.440

Review 3.  [Organ assist devices in the future : Limits and perspectives].

Authors:  R Riessen; U Janssens; S John; C Karagiannidis; S Kluge
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-04-09       Impact factor: 0.840

4.  Predictors of Survival for Patients with Acute Decompensated Heart Failure Requiring Extra-Corporeal Membrane Oxygenation Therapy.

Authors:  A Reshad Garan; Waqas A Malick; Marlena Habal; Veli K Topkara; Justin Fried; Amirali Masoumi; Aws K Hasan; Dimitri Karmpaliotis; Ajay Kirtane; Melana Yuzefpolskaya; Maryjane Farr; Yoshifumi Naka; Dan Burkhoff; Paolo C Colombo; Paul Kurlansky; Hiroo Takayama; Koji Takeda
Journal:  ASAIO J       Date:  2019 Nov/Dec       Impact factor: 2.872

5.  Weaning from veno-arterial extra-corporeal membrane oxygenation: which strategy to use?

Authors:  Sofia Ortuno; Clément Delmas; Jean-Luc Diehl; Clotilde Bailleul; Aymeric Lancelot; Mahassen Naili; Bernard Cholley; Romain Pirracchio; Nadia Aissaoui
Journal:  Ann Cardiothorac Surg       Date:  2019-01

Review 6.  Management of Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock.

Authors:  Steven P Keller
Journal:  Crit Care Med       Date:  2019-09       Impact factor: 7.598

7.  Recovery With Temporary Mechanical Circulatory Support While Waitlisted for Heart Transplantation.

Authors:  Veli K Topkara; Gabriel T Sayer; Kevin J Clerkin; Omar Wever-Pinzon; Koji Takeda; Hiroo Takayama; Craig H Selzman; Yoshifumi Naka; Daniel Burkhoff; Josef Stehlik; Maryjane A Farr; James C Fang; Nir Uriel; Stavros G Drakos
Journal:  J Am Coll Cardiol       Date:  2022-03-08       Impact factor: 24.094

8.  Outcomes of temporary mechanical circulatory support in cardiogenic shock due to end-stage heart failure.

Authors:  Hoong Sern Lim; Aaron Ranasinghe; David Quinn; Colin Chue; Jorge Mascaro
Journal:  J Intensive Care Soc       Date:  2021-01-22

9.  Catheter Ablation in Patients With Cardiogenic Shock and Refractory Ventricular Tachycardia.

Authors:  Jad A Ballout; Oussama M Wazni; Khaldoun G Tarakji; Walid I Saliba; Mohamed Kanj; Mohamed Diab; Mandeep Bhargava; Bryan Baranowski; Thomas J Dresing; Thomas D Callahan; Daniel J Cantillon; John Rickard; David O Martin; Niraj Varma; Mark J Niebauer; Mina K Chung; Patrick J Tchou; Bruce D Lindsay; Ayman A Hussein
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-04-12

10.  An audit of mortality by using ECMO specific scores and APACHE II scoring system in patients receiving extracorporeal membrane oxygenation in a tertiary intensive care unit in Hong Kong.

Authors:  Wai Tsan Ng; Lowell Ling; Gavin M Joynt; Kai Man Chan
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.